Amplex AB publishes supplement to the offer document regarding the cash offer to the shareholders and warrantholders of ADDvise Group AB (publ)

Amplex AB, which announced a cash offer on 10 December 2025 to acquire all shares and warrants in ADDvise Group AB (publ), published on 12 February 2026 a supplement to the offer document that incorporates ADDvise’s year‑end report for the period 1 Jan–31 Dec 2025; the supplement and offer documents are available in Swedish and English on the offer website. The release reiterates detailed jurisdictional distribution restrictions, confirms the Offer is governed by Swedish disclosure and procedural rules (and in the U.S. is made under Section 14(e) relying on the Tier I exemption), and states Amplex reserves the right to purchase ADDvise securities outside the formal offer—items investors should monitor for takeover dynamics and potential price impact.

Analysis

Market structure: The tender offer concentrates control dynamics in a small-cap Swedish life‑science target (ADDvise) and narrows the effective float because Amplex excludes holders in ~15 jurisdictions; that reduces eligible supply and typically increases bid leverage on domestic shareholders. Winners are Amplex (optionality to buy outside the offer) and long holders who can tender; losers are non‑eligible offshore holders (liquidity lock) and short‑term arbitrageurs if spread compresses quickly. Cross‑asset impact is likely idiosyncratic: negligible FX/commodity moves, modest widening of credit spreads for similarly sized private‑takeover targets, and a short‑term bump in implied equity vols for ADDvise and peer small‑cap Swedish life‑science names.

Risk assessment: Tail risks include a competing bidder (10–25% upside shock), failure to reach acceptance due to jurisdictional ineligibility or negative earnings in the published year‑end (20–30% downside shock), or Amplex accumulating blocks off‑market (price gap squeeze). Immediately (days) expect elevated tradeable spread and spikes in volume/vol; short‑term (weeks–months) resolution as tender closes or creeping purchases occur; long‑term (quarters) outcome is binary: delisting/privatization or re‑rated public equity. Hidden dependency: warrants’ conversion mechanics can alter required cash consideration and float; regulatory/filing thresholds (Swedish takeover rules) are the decisive catalyst.

Trade implications: Primary direct play is classic tender arbitrage: long ADDvise up to the offer price if market trades ≥2% below announced consideration, size 1–3% NAV with a stop at 1.5% NAV loss or if spread tightens to <0.5% within 7 trading days; hedge 30–50% with short exposure to the OMXSPI for market beta removal. Buy warrants if implied conversion yields ≥1.5% extra arbitrage after fees and exercise mechanics (size 0.5–1% NAV). Options: buy near‑dated call spreads if implied vol <40% and you want capped risk; sell short dated calls to finance position only if spread is stable. Rotate 10–20% of small‑cap life‑science exposure into larger, liquid Swedish pharma/service names to reduce event risk.

Contrarian angles: The market may underprice the risk that jurisdictional exclusions reduce tender participation—this can make the deal easier for Amplex (less share supply to purchase) or harder (offshore holders hold blocking stakes). The consensus that the offer is low‑impact is likely underdone because warrants and off‑market purchase rights create asymmetric upside for an active acquirer; historical Swedish small‑cap takeovers have produced 15–40% control premia when competing bids or creeping buys occur. Unintended consequence: a failed tender could leave a fractured float, raising post‑deal illiquidity and persistent discount of 20–50% over 6–12 months.

Key Decisions for Investors

• If ADDvise trades ≥2% below the announced cash consideration, establish a long position sized 1–3% of NAV with a target hold until tender close (expected within 1–3 months); hedge 30–50% of position with a short in OMXSPI to remove market beta; exit if spread narrows below 0.5% or if stop triggers at a 1.5% NAV loss.
• If warrants of ADDvise price implies >1.5% incremental arbitrage after exercise/fees, buy warrants sized 0.5–1.0% NAV and hold to exercise/settlement; liquidate if implied arbitrage compresses below 0.5% or if Amplex publicly announces off‑market block purchases.
• Deploy a discretionary 0.5% NAV long call‑spread (buy near ITM, sell 10–15% OTM) expiring 2–3 months out if implied vol <40% to capture upside from a competing bid or creeping purchase without full equity exposure; close on material corporate disclosures.
• Reduce aggregate exposure to small‑cap Swedish life‑science names by 10–20% over the next 30 days and reallocate into larger, liquid Stockholm‑listed pharma/service equities (e.g., Recipharm or equivalent) to lower event‑specific take‑private risk.
• Set market alerts: (a) any regulatory filing or press release from Amplex or ADDvise; (b) any block trade >1% of ADDvise shares; (c) warrant conversion announcements—act within 24 hours (increase/decrease positions) when any trigger fires.